There are 2789 resources available
742P - Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs): A US real-world (RW) analysis
Presenter: Dana Chase
Session: ePoster Display
743P - Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
Presenter: Rohan Shotton
Session: ePoster Display
680P - Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study
Presenter: Janet Brown
Session: ePoster Display
681P - Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
Presenter: Saby George
Session: ePoster Display
682P - Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)
Presenter: Daniel Geynisman
Session: ePoster Display
737P - Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)
Presenter: Natalie Ngoi
Session: ePoster Display
738P - Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
Presenter: Maria-Pilar Barretina-Ginesta
Session: ePoster Display
671P - Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries
Presenter: Rachel Giles
Session: ePoster Display
672P - Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
Presenter: Giuseppe Procopio
Session: ePoster Display